Understanding side effects of combined cancer treatments
Official title: Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry
Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT04115267 · Data updated 2026-11-12
This study is trying to see how often severe side effects happen when people with cancer receive both molecular therapies and radiotherapy together compared to when they get them separately.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3600 (estimated) |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Drugs / interventions | Radiation, immunotherapy |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | September 13, 2019 |
| Main results expected | September 30, 2030 |
| Study ends | September 30, 2030 |
| Registry record updated | August 14, 2026 |
| Trial ID | NCT04115267 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old with a histological diagnosis of primary cancer who are receiving molecular therapy and are indicated for radiotherapy.
✕Probably not a fit
Patients who refuse or are unable to receive radiotherapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry aims to gather data from patients receiving both molecular therapies and radiotherapy for cancer. It focuses on collecting information about diagnoses, treatment doses, types of therapies, and reported side effects. By analyzing this data, the study seeks to determine the prevalence of severe side effects when these treatments are used together compared to when they are used separately. Patient-reported outcomes regarding their quality of life and perceived side effects will also be included in the analysis.
Why it matters
Potential benefit: If successful, this study could lead to improved management of side effects for cancer patients undergoing combined treatments.
How similar studies have gone: While there have been studies on the effects of individual treatments, this registry approach to understanding the combined effects of molecular therapies and radiotherapy is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consent to be part of the AtTRIBut registry * Prior histological diagnosis of primary cancer. * If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis * Age\> 18 years * Receiving a molecular therapy * Indicated to receive radiotherapy * Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques. Exclusion Criteria: • Refusal or inability to receive radiotherapy
Where it's running
-
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Philip Wong, MD — Chum
- Study coordinator: Mom Phat, RN
- Email: mom.phat.chum@ssss.gouv.qc.ca
- Phone: 1-514-8908000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Self‑manual lymph drainage for head and neck lymphedema
This trial will test whether different intensities of self‑applied manual lymph drainage help people with head and neck lymphedema after radiotherapy for oropharyngeal cancer.
-
Health-Oriented Protocol for Epidermal Radiodermatitis
This study looks at how skin reactions from radiation therapy affect adults with head/neck or pelvic cancers and whether certain factors influence RID outcomes.
-
Skipping the clinical target volume (CTV) around the primary tumor in limited-stage small cell lung cancer
This trial tests whether giving chest radiotherapy that skips the usual extra margin around the main tumor is as effective and causes fewer side effects for people with limited-stage small cell lung cancer who have responded to initial chemotherapy.
-
Curative chest re‑irradiation for thoracic cancers
This project will try a standardized high‑dose re‑radiation approach for adults with recurrent or new thoracic cancers who previously received chest radiotherapy to see how well it controls disease and what toxicities occur.
-
Radiotherapy for Head and Neck Cancer with Simultaneous Integrated Boost
This study is testing a new type of radiation therapy for people with head and neck cancer to see if it helps them live longer and feel better while causing fewer side effects.
-
Comparing total neoadjuvant therapy with surgery for rectal cancer treatment
This study is testing if rectal cancer patients who respond well to a new treatment can skip surgery and just be monitored to see how they do compared to those who have surgery right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.